MAP2K7 and melanoma: Immune checkpoint inhibitors (ICIs) and targeted therapy with combined BRAF and MEK inhibitors (BRAF/MEKi) have completely transformed the therapeutic landscape for patients with advanced melanoma [1,2,3,4,5,6,7,8,9].